

Product Information  Information du Produit®

IMPORTANT PRODUCT FORMAT DISCONTINUATIONS

We would like to notify you that, effective immediately, Novartis Pharmaceuticals Canada Inc. is discontinuing the sale of the following product format:

Product	Molecule	Strength	Form	Size	DIN	Product Code
®Estracomb®	estradiol-norethindrone acetate+estradiol	50 mg	Patch	8	02108186	3819

Current inventories should be depleted prior to discontinuing the products in your systems. The standard terms of the Novartis Pharmaceuticals trade policy will apply.

Should you require additional information, please contact our *Customer Relations Department at 1-800-465-2244.*

Product Information  Information du Produit®

CHANGE TO PRODUCT

This is to inform you that there has been a change in the appearance of Tegretol 200 mg as a result of a manufacturing site transfer.

Current Tablets	New Tablets
Engraved GEIGY on one side and quadrisected on the other	Breakline on one face and impressed TEGRETOL 200 on the other.

The first lots of Tegretol 200 mg tablets were manufactured at the new site in Feb 2009.

Also note that the product composition and the packaging components remain the same (HDPE bottles), but the size of the 100's and 500's bottles have decreases.

Please communicate this information to all you colleagues and customers.

Formulary

AEROCHAMBER® BRAND AC GIRLZ™ & AC BOYZ™ CHAMBERS: NOW COVERED BY ALBERTA HEALTH & WELLNESS

Trudell Medical International is pleased to announce that **AC Girlz™** and **AC Boyz™** Chambers are now covered by Alberta Health and Wellness effective April 1st, 2009.

AeroChamber® Brand **AC Girlz™** and **AC Boyz™** Chambers are also covered by Private Insurance plans and the following provincial formularies.

	AC Girlz™ Chamber	AC Boyz™ Chamber
UPC	7 62860 01481 7	7 62860 01482 4
Alberta Health & Wellness	00000990088	00000990089
Saskatchewan Health	00404347	00404347
Manitoba Pharmacare	00900210	00900210
Quebec RAMQ	99002116	99002116
New Brunswick Health Services	Submit convalescent equipment requisition form	



www.trudellmed.com
1-866-510-0004

™/® trade-marks and registered trade-marks of or used under licence by Trudell Medical International. ©Trudell Medical International 2009. All rights reserved.



What topics would you like to see covered in potential future editorial stories?

- Reducing your taxes _____
- Managing staff _____
- Store security _____
- Privacy laws _____
- Internet dispensing _____
- Consumer counseling _____
- Inventory management _____
- CHE requirements _____

Please fax to: 1-800-420-3616

It affects 60% of women. Shouldn't you know more about it?


NOW AVAILABLE

On-line, on your time, 24 hour a day access, National CCCEP & OPQ Accredited Program:

Unravelling Urinary Tract Infections: What Pharmacists Need to Know.

Sign up now at www.uti-treatments.ca

Program sponsored by an educational grant from





PRICE REDUCTION FOR ELIGARD 45MG (6-MONTH) EFFECTIVE JULY 1ST, 2009

Sanofi-aventis Canada Inc. would like to inform you of a price reduction on ELIGARD® 45mg (6-Month) across Canada, effective July 1st 2009.

DIN	PRODUCT	FORMAT	PRICE
02268892	ELIGARD® 45mg (6-Month)	1	\$1,450.00

Provincial drug plan managers have been informed of the price decrease as of July 1st, 2009. Therefore, we invite you to manage and sell your current inventory in anticipation of the upcoming change to the provincial reimbursement price.

If you have any questions, please communicate with our Customer Service Department at 1-800-265-7927.



NEW REVISED ODBF REIMBURSEMENT CODES FOR PLAVIX®

Effective May 20th, 2009, the ODBF Limited Use codes for PLAVIX® have been revised. Please note the revisions to the criteria for the existing codes (i.e. 375 and 376) as well as the addition of a new code (i.e. 411).

For access to the criteria, please consult the ODBF website.

MI, Stroke or Established Peripheral Arterial Disease


PLAVIX® is indicated for the secondary prevention of atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with atherosclerosis documented by stroke, MI, or established peripheral arterial disease.

Acute Coronary Syndrome

PLAVIX®, in combination with acetylsalicylic acid (ASA), is indicated for the early and long-term secondary prevention of atherothrombotic events (myocardial infarction, ischemic stroke, cardiovascular death and/or refractory ischemia) in patients with acute coronary syndromes - without ST-segment elevation (i.e. unstable angina or non-Q-wave myocardial infarction). These benefits of PLAVIX® have been shown only when these patients were concomitantly treated with ASA in addition to other standard therapies.

These benefits were also seen in patients who were managed medically and those who were managed with percutaneous coronary intervention (with or without stent) or CABG (coronary artery bypass graft).

For patients with ST-segment elevation acute myocardial infarction, PLAVIX® has been shown to reduce the rate of an endpoint of all-cause mortality and the rate of a combined endpoint of death, reinfarction, or stroke.



Plavix® Registered trade-mark of sanofi-aventis, co-promoted by sanofi-aventis Canada Inc. and Bristol-Myers Squibb Canada Co.

CDN.CLO.09.04.07E



DIHYDROERGOTAMINE (DHE) 1 MG/ML

SteriMax Inc. wishes to remind pharmacists that Dihydroergotamine (DHE) 1 mg/ml (DIN 00027243, UPC 834324000091) is in stock and available to order.

Dihydroergotamine is listed on the AB, BC, MB, NB, NS, QC and SK Formularies.

To order Dihydroergotamine (DHE) 1 mg/ml, please contact your preferred wholesaler or SteriMax Inc. customer service at 1-800-881-3550. Please also visit our website at www.sterimaxinc.com.

Dihydroergotamine (DHE) 1 mg/ml ST-00900	
Wholesaler	Wholesaler Item Number
AmerisourceBergen Canada	7505002
Kohl & Frisch	29971
Lawton	2005002
McKesson	181438
Procurity	83432400009
Shoppers Drug Mart	834324000091
Unipharm	00194159
Value Drug Mart	14931

**FREE CLASSIFIED ADVERTISING
FOR PHARMACISTS/**

**GRATUITS POUR PHARMACIENS
L'ÉCHANGE PHARMACIEN À PHARMACIEN®**



FAX / TÉLÉCOPIEUR SANS FRAIS:

1-800-420-3616



EMAIL / COURRIEL:

contact@ipharmadirect.com

CATEGORY / CATÉGORIE

- Career Opportunities / Perspectives de carrière
- Pharmacy for Sale / Pharmacie à vendre
- Pharmacy Wanted / Pharmacie demandée
- For Sale - Pharmacy Store/Equipment / À vendre - Équipement de pharmacie
- Pharmacist Available / Pharmacien - disponible
- Vacation Spots / Endroits de vacances
- Seminars / Courses / Conférences et séminaires
- For Sale - Miscellaneous / À vendre - divers
- Other / Autre

**Visit us at
www.ipharmadirect.com**